Chronic myeloid leukemia

New England Journal of Medicine

Volumn 340, Issue 17, 1999, Pages 1330-1340

  Sawyers, Charles L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BUSULFAN; CYTARABINE; HYDROXYUREA;

BONE MARROW APLASIA; BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CHROMOSOME ABERRATION; CHRONIC MYELOID LEUKEMIA; GASTROINTESTINAL SYMPTOM; GRAFT VERSUS HOST REACTION; HISTOPATHOLOGY; HUMAN; LEUKEMOGENESIS; LEUKOPENIA; MUCOSA INFLAMMATION; MYALGIA; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; RASH; REVIEW; TREATMENT PLANNING;

ANTINEOPLASTIC AGENTS; BONE MARROW TRANSPLANTATION; COMBINED MODALITY THERAPY; FUSION PROTEINS, BCR-ABL; GENES, ABL; GRAFT VS TUMOR EFFECT; HUMANS; INTERFERON-ALPHA; LEUKEMIA, MYELOID, CHRONIC; REMISSION INDUCTION; SIGNAL TRANSDUCTION; TRANSPLANTATION, AUTOLOGOUS;

EID: 0033614446     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199904293401706     Document Type: Review

References (98)

1. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science 1960;132:1497. abstract.
2. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Gicmsa staining. Nature 1973;243:290-3.
3. Bernstein R. Cytogenetics of chronic myelogenous leukemia. Semin Hematol 1988;25:20-34.
4. Sill H, Goldman JM, Cross NC. Homozygous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia. Blood 1995;85:2013-6.
5. Ahuja H, Bar-Eli M, Arlin Z, et al. The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia. J Clin Invest 1991; 87:2042-7.
6. Pane F, Frigeri F, Sindona M, et al. Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker. Blood 1996;88: 2410-4. [Erratum, Blood 1997;89:4244.]
7. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990;247:1079-82.
8. Voncken JW, Kaartinen V, Pattengale PK, Germeraad WT, Groffen J, Heisterkamp N. BCR/ABL P210 and P190 cause distinct leukemia in transgenic mice. Blood 1995;86:4603-11.
9. Tkachuk DC, Westbrook CA, Andreeff M, et al. Detection of bcr-abl fusion in chronic myelogenous leukemia by in situ hybridization. Science 1990;250:559-62.
10. Cross NC, Feng L, Chase A, Bungey J, Hughes TP, Goldman JM. Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts of chronic myeloid leukemia patients after bone marrow transplantation. Blood 1993;82:1929-36.
11. Kantarjian HM, Smith TL, O'Brien S, Beran M, Pierce S, Talpaz M. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy. Ann Intern Med 1995;122:254-61.
12. Hughes TP, Morgan GJ, Martiat P, Goldman JM. Detection of residual leukemia after bone marrow transplant for chronic myeloid leukemia: role of polymerase chain reaction in predicting relapse. Blood 1991;77:874-8.
13. Radich JP, Gehly G, Gooley T, et al. Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. Blood 1995;85:2632-8.
14. Hochhaus A, Lin F, Reiter A, et al. Variable numbers of BCR-ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon-alpha. Br J Haematol 1995;91:126-31.
15. Miyamura K, Tahara T, Tanimoto M, et al. Long persistent bcr-abl positive transcript detected by polymerase chain reaction after marrow transplant for chronic myelogenous leukemia without clinical relapse: a study of 64 patients. Blood 1993;81:1089-93.
16. Heisterkamp N, Jenster G, ten Hoeve J, Zovich D, Pattengale PK, Groffen J. Acute leukaemia in bcr/abl transgenic mice. Nature 1990;344: 251-3.
17. Voncken JW, Morris C, Pattengale P, et al. Clonal development and karyotype evolution during leukemogenesis of BCR/ABL transgenic mice. Blood 1992;79:1029-36.
18. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990;247:824-30.
19. Kelliher MA, McLaughlin J, Witte ON, Rosenberg N. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR-ABL. Proc Natl Acad Sci U S A 1990;87:6649-53. [Erratum, Proc Natl Acad Sci U S A 1990;87:9072.]
20. Elefanty AG, Hariharan IK, Cory S. bcr-abl, The hallmark of chronic myeloid leukaemia in man, induces multiple haematopoietic neoplasms in mice. EMBO J 1990;9:1069-78.
21. McLaughlin J, Chianese E, Witte O. In vitro transformation of immature hematopoictic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome. Proc Natl Acad Sci U S A 1987;84:6558-62.
22. Gishizky ML, Witte ON. Initiation of deregulated growth of multipotent progenitor cells by bcr-abl in vitro. Science 1992;256:836-9.
23. Nishii K, Kabarowski JH, Gibbons DL, et al. ts BCR-ABL kinase activation confers increased resistance to genotoxic damage via cell cycle block. Oncogene 1996;13;2225-34.
24. Evans CA, Owen-Lynch PJ, Whetton AD, Dive C. Activation of the Abelson tyrosine kinase activity is associated with suppression of apoptosis in hemopoietic cells. Cancer Res 1993;53:1735-8.
25. Amos TA, Lewis JL, Grand FH, Gooding RP, Goldman JM, Gordon MY. Apoptosis in chronic myeloid leukaemia: normal responses by progenitor cells to growth factor deprivation, X-irradiation and glucocorticoids. Br J Haematol 1995;91:387-93.
26. Albrecht T, Schwab R, Henkes M, Peschel C, Huber C, Aulitzky WE. Primary proliferating immature myeloid cells from CML patients are not resistant to induction of apoptosis by DNA damage and growth factor withdrawal. Br J Haematol 1996;95:501-7.
27. Bazzoni G, Carlesso N, Griffin JD, Hemler ME. Bcr/Abl expression stimulates integrin function in hematopoietic cell lines. J Clin Invest 1996; 98:521-8.
28. Senechal K, Heaney C, Druker B, Sawyers CL. Structural requirements for function of the Crkl adapter protein in fibroblasts and hematopoietic cells. Mol Cell Biol 1998;18:5082-90.
29. Gordon MY, Dowding CR, Riley GP, Goldman JM, Greaves MF. Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia. Nature 1987;328:342-4.
30. Bhatia R, McCarthy JB, Verfaillie CM. Interferon-alpha restores normal beta 1 integrin-mediated inhibition of hematopoietic progenitor proliferation by the marrow microenvironment in chronic myelogenous leukemia. Blood 1996;87:3883-91.
31. Van Etten RA, Jackson P, Baltimore D. The mouse type IV c-abl gene product is a nuclear protein, and activation of transforming ability is associated with cytoplasmic localization. Cell 1989;58:669-78.
32. Lewis JM, Baskaran R, Taagepera S, Schwartz MA, Wang JYJ. Integrin regulation of c-Abl tyrosine kinase activity and cytoplasmic-nuclear transport. Proc Natl Acad Sci U S A 1996;93:15174-9.
33. Nichols GL, Raines MA, Vera JC, Lacomis L, Tempst P, Golde DW. Identification of CRKL as the constitutively phosphorylated 39-kD tyrosine phosphoprotein in chronic myelogenous leukemia cells. Blood 1994; 84:2912-8.
34. + leukemia. Blood 1994; 94:1731-6.
35. Oda T, Heaney C, Hagopian JR, Okuda K, Griffin JD, Druker BJ. Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J Biol Chem 1994;269:22925-8.
36. dok: A constitutively tyrosine-phosphorylated, GAP-associated protein in chronic myelogenous leukemia progenitor cells. Cell 1997;88:197-204.
37. Yamanashi Y, Baltimore D. Identification of the Abl- and rasGAP-associated 62 kDa protein as a docking protein, Dok. Cell 1997;88:205-11.
38. Salgia R, Uemura N, Okuda K, et al. CRKL links p210BCR/ABL with paxillin in chronic myelogenous leukemia cells. J Biol Chem 1995; 270:29145-50.
39. de Jong R, ten Hoeve J, Heisterkamp N, Groffen J. Crkl is complexed with tyrosine-phosphorylated Cbl in Ph-positive leukemia. J Biol Chem 1995;270:21468-71.
40. Afar DE, Han L, McLaughlin J, et al. Regulation of the oncogenic activity of BCR-ABL by a tightly bound substrate protein RIN1. Immunity 1997;6:773-82.
41. Mandanas RA, Leibowitz DS, Gharehbaghi K, et al. Role of p21 RAS in p210 bcr-abl transformation of murine myeloid cells. Blood 1993;82: 1838-47.
42. Okuda K, Marulonis U, Salgia R, Kanakura Y, Druker B, Griffin JD. Factor independence of human myeloid leukemia cell lines is associated with increased phosphorylation of the proto-oncogene Raf-1. Exp Hematol 1994;22:1111-7.
43. Skorski T, Kanakaraj P, Nieborowska-Skorska M, et al. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood 1995;86:726-36.
44. Raitano AB, Halpern JR, Hambuch TM, Sawyers CL. The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. Proc Natl Acad Sci U S A 1995;92:11746-50.
45. Sawyers CL, Callahan W, Witte ON. Dominant negative MYC blocks transformation by ABL oncogenes. Cell 1992;70:901-10.
46. Shuai K, Halpern J, ten Hoeve J, Rao X, Sawyers CL. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene 1996;13:247-54.
47. Carlesso N, Frank DA, Griffin JD. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J Exp Med 1996;183:811-20.
48. Ilaria RL Jr, Van Etten RA. P210 and P190 (BCR/ABL) induce the tyrosinc phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem 1996;271:31704-10.
49. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-6.
50. Sawyers CL, McLaughlin J, Witte ON. Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene. J Exp Med 1995;181:307-13.
51. Skorski T, Bellacosa A, Nieborowska-Skorska M, et al. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J 1997;16:6151-61.
52. Dickens M, Rogers JS, Cavanagh J, et al. A cytoplasmic inhibitor of the JNK signal transduction pathway. Science 1997;277:693-6.
53. Afar DEH, Goga A, McLaughlin J, Witte ON, Sawyers CL. Differential complementation of Bcr-Abl point mutants with c-Myc. Science 1994; 264:424-6.
54. Hehlmann R, Heimpel H, Hasford J, et al. Randomized comparison of Interferon-α with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood 1994;84:4064-77.
55. Ohnishi K, Ohno R, Tomonaga M, et al. A randomized trial comparing interferon-α with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 1995;86:906-16.
56. Guilhot F, Chastang C, Michallet M, et al. Interferon alpha-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med 1997;337:223-9.
57. Horowitz MM, Rowlings PA, Passweg JR. Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant 1996;17:Suppl 3:S5-S6.
58. vin Rhee F, Szydlo RM, Hermans J, et al. Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1997;20:553-60.
59. Clift RA, Anasetti C. Allografting for chronic myeloid leukaemia. Baillieres Clin Haematol 1997;10:319-36.
60. McGlave P, Bartsch G, Anasetti C, et al. Unrelated donor marrow transplantation therapy for chronic myelogenous leukemia: initial experience of the National Marrow Donor Program. Blood 1993;81:543-50.
61. McGlave P, Kollman C, Shu XO, et al. The first 1000 unrelated donor transplants for CML: lessons from the National Marrow Donor Program (NMDP) experience. Blood 1996;88:Suppl 1:483a. abstract.
62. Hansen JA, Gooley TA, Martin PJ, et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 1998;338:962-8.
63. Thomas ED, Clift RA, Fefer A, et al. Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 1986;104: 155-63.
64. O'Brien SG. Autografting for chronic myeloid leukaemia. Baillieres Clin Haematol 1997;10:369-88.
65. Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED, Seattle Marrow Transplant Team. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow trans plantation. N Engl J Med 1981;304:1529-33.
66. Goldman JM, Gale RP, Horowitz MM, et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: increased risk for relapse associated with T-cell depletion. Ann Intern Med 1988;108: 806-14.
67. Kolb HJ, Mittermuller J, Clemm C, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990;76:2462-5.
68. Drobyski WR, Keever CA, Roth MS, et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood 1993;82:2310-8.
69. Porter DL, Roth MS, McGarigle C, Ferrara JLM, Antin JH. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 1994;330:100-6.
70. Mackinnon S, Papadopoulos EB, Carabasi MH, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995;86:1261-8.
71. Bocchia M, Korontsvit T, Xu Q, et al. Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood 1996;87:3587-92.
72. + T cells with cytotoxic activity against leu kemic cells from patients with chronic myeloid leukemia. Blood 1998;91: 977-83.
73. Talpaz M, McCredie KB, Mavligit GM, Gutterman JU. Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. Blood 1983;62:689-92.
74. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 1994;330:820-5.
75. Allan NC, Richards SM, Shepherd PC. UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. Lancet 1995;345:1392-7.
76. The Chronic Mycloid Leukemia Trialists' Collaborative Group. Interfeton alpha versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials. J Natl Cancer Inst 1997;89: 1616-20.
77. Friedman RL, Stark GR. alpha-Interferon-induced transcription of HLA and metallothionein genes containing homologous upstream sequences. Nature 1985;314:637-9.
78. Lardon F, Snoeck HW, Berneman ZN, et al. Generation of dendritic cells from bone marrow progenitors using GM-CSF, TNF-alpha, and additional cytokines: antagonistic effects of IL-4 and IFN-gamma and selective involvement of TNF-alpha receptor-1. Immunology 1997;91:553-9.
79. Choudhury A, Gajewski JL, Liang JC, et al. Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 1997; 89:1133-42.
80. Lee SI, Kuntz KM, Horowitz MM, et al. Unrelated donor bone marrow transplantation for chronic myeiogenous leukemia: a decision analysis. Ann Intern Med 1997;127:1080-8.
81. Beelen DW, Graeven U, Elmaagacli AH, et al. Prolonged administration of interferon-alpha in patients with chronic-phase Philadelphia chromosome-positive chronic myciogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome. Blood 1995;85:2981-90.
82. Giralt SA, Kantarjian HM, Talpas M, et al. Effect of prior interferon alpha therapy on the outcome of allogenek bone marrow transplantation for chronic myelogenous leukemia. J Clin Oncol 1993;11:1055-61.
83. Zuffa E, Bandini G, Bonini A, et al. Prior treatment with alpha-interferon does not adversely affect the outcome of allogeneic BMT in chronic phase chronic mycloid leukemia. Haematologica 1998;83:231-6.
84. Higano CS, Chiclens D, Raskind W, et al. Use of alpha-2a-interferon to treat cytogenetic relapse of chronic myeloid leukemia after marrow transplantation. Blood 1997;90:2549-54.
85. Arcese W, Goldman JM, D'Arcangelo E, et al. Outcome for patients who relapse after allogeneic bone marrow transplantation for chronic myeloid leukemia. Blood 1993;82:3211-9.
86. Sharp JC, Joyner MV, Wayne AW, et al. Karyotypic conversion in Ph1-positive chronic myeloid leukaemia with combination chemotherapy. Lancet 1979;1:1370-2.
87. Smalley KV, Vogel J, Huguley CM Jr, Miller D. Chronic granulocytic leukemia: cytogenetic conversion of the bone marrow with cycle-specific chemotherapy. Blood 1977;80:107-13.
88. Carella AM, Chimirri P, Podesta M, et al. High-dose chemo-radiotherapy followed by autologous Philadelphia chromosome-negative blood progenitor cell transplantation in patients with chronic myelogenous leukemia. Bone Marrow Transplant 1996;17:201-5.
89. McGlave PB, De Fabritis P, Deisscroth A, et al. Autologous transplants for chronic myelogenous leukaemia; results from eight transplant groups, Lancet 1994;348:1486-8.
90. Reiffess L, Goldman J, Maloni G, Cahn JY, Gratwohl A. Autologous stem cell transplantation in chronic myclogenous leukemia: a retrospective analysis of the European Group for Bone Marrow Transplantation. Bone Marrow Transplant 1994;14:407-10.
91. Deisseroth AB, Zu Z, Claxton D, et al. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 1994;83:3068-76.
92. de Fabritiis P, Amadori S, Petti MC, et al. In vitro purging with BCR-ABL antisense oligodeoxynucleotides does not prevent haematologic reconstitution after autologous bone marrow transplantation. Leukemia 1995;9:662-4.
93. Gewirtz AM. Treatment of chronic myelogenous leukemia (CML) with c-myb antiscense oligodeoxynucleotides. Bone Marrow Transplant 1994;14:Suppl 3:S57-S61.
94. Barnett MJ, Eaves CJ, Phillips GL, et al. Autografting with cultured marrow in chronic myeloid leukemia: results of a pilot study. Blood 1994; 84:724-32.
95. Verfaillie CM, Bhatia R, Miller W, et al. BCR/ABL-negative primitive progenitors suitable for transplantation can be selected from the marrow of most early-chronic phase but not accelerated-phase chronic myelogenous leukemia patients. Blood 1996;87:4770-9.
96. Toren A, Ackerstein A, Slavin S, Nagler A. Role of interleukin-2 in human hematological malignancies. Med Oncol 1995;12:177-86.
97. Cortez D, Stoica G, Pierce JH, Pendergast AM. The BCR-ABL tyrosine kinase inhibits apoptosis by activating a Ras-dependent signaling pathway. Oncogene 1996;13:2589-94.
98. Gibbs JB, Oliff A, Kohl NE. Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell 1994;77:175-8.